Literature DB >> 31042471

Costimulation Induces CD4 T Cell Antitumor Immunity via an Innate-like Mechanism.

Crystal Morales Del Valle1, Joseph R Maxwell1, Maria M Xu1, Antoine Menoret1, Payal Mittal1, Naomi Tsurutani1, Adam J Adler2, Anthony T Vella3.   

Abstract

Chronic exposure to tumor-associated antigens inactivates cognate T cells, restricting the repertoire of tumor-specific effector T cells. This problem was studied here by transferring TCR transgenic CD4 T cells into recipient mice that constitutively express a cognate self-antigen linked to MHC II on CD11c-bearing cells. Immunotherapeutic agonists to CD134 plus CD137, "dual costimulation," induces specific CD4 T cell expansion and expression of the receptor for the Th2-associated IL-1 family cytokine IL-33. Rather than producing IL-4, however, they express the tumoricidal Th1 cytokine IFNγ when stimulated with IL-33 or IL-36 (a related IL-1 family member) plus IL-12 or IL-2. IL-36, which is induced within B16-F10 melanomas by dual costimulation, reduces tumor growth when injected intratumorally as a monotherapy and boosts the efficacy of tumor-nonspecific dual costimulated CD4 T cells. Dual costimulation thus enables chronic antigen-exposed CD4 T cells, regardless of tumor specificity, to elaborate tumoricidal function in response to tumor-associated cytokines.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31042471      PMCID: PMC6508096          DOI: 10.1016/j.celrep.2019.04.016

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  90 in total

1.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

2.  T cell and APC dynamics in situ control the outcome of vaccination.

Authors:  Kamal M Khanna; David A Blair; Anthony T Vella; Stephen J McSorley; Sandip K Datta; Leo Lefrançois
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

Review 3.  Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.

Authors:  Paolo A Ascierto; Ester Simeone; Mario Sznol; Yang-Xin Fu; Ignacio Melero
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

4.  Innate lymphoid cell function in the context of adaptive immunity.

Authors:  Jennifer K Bando; Marco Colonna
Journal:  Nat Immunol       Date:  2016-06-21       Impact factor: 25.606

5.  IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells.

Authors:  Liying Guo; Gang Wei; Jinfang Zhu; Wei Liao; Warren J Leonard; Keji Zhao; William Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-29       Impact factor: 11.205

6.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function.

Authors:  Seung-Joo Lee; Lara Myers; Guruprasaadh Muralimohan; Jie Dai; Yi Qiao; Zihai Li; Robert S Mittler; Anthony T Vella
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

Review 8.  Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.

Authors:  Miguel F Sanmamed; Fernando Pastor; Alfonso Rodriguez; Jose Luis Perez-Gracia; Maria E Rodriguez-Ruiz; Maria Jure-Kunkel; Ignacio Melero
Journal:  Semin Oncol       Date:  2015-06-11       Impact factor: 4.929

9.  Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression.

Authors:  P Zhang; F Gao; Q Wang; X Wang; F Zhu; C Ma; W Sun; L Zhang
Journal:  Scand J Immunol       Date:  2007-10       Impact factor: 3.487

10.  Innate immunological function of TH2 cells in vivo.

Authors:  Liying Guo; Yuefeng Huang; Xi Chen; Jane Hu-Li; Joseph F Urban; William E Paul
Journal:  Nat Immunol       Date:  2015-08-31       Impact factor: 25.606

View more
  2 in total

Review 1.  IL-36 in chronic inflammation and fibrosis - bridging the gap?

Authors:  Michael Elias; Shuai Zhao; Hongnga T Le; Jie Wang; Markus F Neurath; Clemens Neufert; Claudio Fiocchi; Florian Rieder
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

2.  Nicotinamide breaks effector CD8 T cell responses by targeting mTOR signaling.

Authors:  Federica Agliano; Timofey A Karginov; Antoine Ménoret; Anthony Provatas; Anthony T Vella
Journal:  iScience       Date:  2022-02-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.